SCHEMBL4489487

SCHEMBL4489487

COc1cc2cc(C(=O)O)c(Nc3cccc(Cl)c3)nc2cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.61
MAPT P10636 5/20 0.56
KDM4E B2RXH2 4/20 0.56
LMNA P02545 3/20 0.54
HPGD P15428 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MAPK1 P28482 2/20 0.54
ALDH1A1 P00352 2/20 0.54
TP53 P04637 2/20 0.54
ALOX15 P16050 2/20 0.54
HSD17B10 Q99714 2/20 0.54
TNF P01375 1/20 0.54
GMNN O75496 1/20 0.54
ABL1 P00519 1/20 0.54
RAF1 P04049 1/20 0.54
CYP1A2 P05177 1/20 0.54
GLA P06280 1/20 0.54
CYP3A4 P08684 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8154691 0.86 EGFR (0.61) EGFRMAPTKDM4ELMNAHPGD
SCHEMBL5205074 0.85 MEN1 (0.64) EGFRMAPTLMNAHPGDMEN1
SCHEMBL5207437 0.85 MEN1 (0.64) EGFRMAPTKDM4ELMNAHPGD
SCHEMBL5204584 0.83 CSNK2A1 (0.56) LMNAHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL5207731 0.81 ALDH1A1 (0.52) EGFRLMNAHPGDMEN1KMT2A
SCHEMBL5202960 0.81 CSNK2A1 (0.61) EGFRKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL4498882 0.81 MEN1 (0.52) EGFRMAPTKDM4ELMNAHPGD
SCHEMBL4503390 0.80 PIM1 (0.55) EGFRMEN1KMT2ACSNK2A2CSNK2B
SCHEMBL5204744 0.79 CSNK2A1 (0.49) LMNAHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL5202883 0.79 CSNK2A1 (0.49) LMNAHPGDMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 EGFR 4215/4885MAPT 3468/4885KDM4E 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.